Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ProstVac: Phase I data

In a National Cancer Institute-conducted Phase I trial of fixed-dose ProstVac and GM-CSF combined with escalating doses of ipilimumab, the 24 chemotherapy-naïve patients had a median PSA DT increase to 6 months from

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers